StockData

Drugs Made In America Acquisition Corp. (DMAA) stock

DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)

Close on Nov 16, 2026Market cap $264.62MP/E –Yield –

Drugs Made In America Acquisition cash

Cash and short-term investments held at the end of each period.

Drugs Made In America Acquisition's cash was $20.28K at Jun 30, 2026. For fiscal 2025 it was $6.14K, up 354.3% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.14K+354.3%
FY2024Dec 31, 2024$1.35K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$20.28K+2367.2%
Q1 FY2026Mar 31, 2026$14.89K+1711.1%
Q4 FY2025Dec 31, 2025$6.14K+354.3%
Q3 FY2025Sep 30, 2025$717-65.8%
Q2 FY2025Jun 30, 2025$822-95.5%
Q1 FY2025Mar 31, 2025$822–
Q4 FY2024Dec 31, 2024$1.35K–
Q3 FY2024Sep 30, 2024$2.10K–
Q2 FY2024Jun 30, 2024$18.10K–

More Drugs Made In America Acquisition figures

See a number that looks wrong?